Evaluation of the effectiveness of prophylactic oral vitamin D (cholecalciferol) in children with sickle cell disease

Vitamin D (25(OH)D) deficiency has become an emerging public health problem due to its influence on skeletal and extraskeletal diseases. Bone health in patients with sickle cell disease (SCD) is especially compromised and they are more likely to have 25(OH)D deficiency than the general population. D...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bone (New York, N.Y.) N.Y.), 2020-04, Vol.133, p.115228-115228, Article 115228
Hauptverfasser: Garrido, Carmen, Bardón-Cancho, Eduardo J., Fajardo-Sánchez, Verónica de los Ángeles, Cascón-Pérez-Teijón, María Elena, García-Morín, Marina, Cela, Elena, Beléndez, Cristina, Mata-Fernández, Cristina, Huerta-Aragonés, Jorge, Escobar-Fernández, Laura, Béliz-Mendiola, Cristina
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Vitamin D (25(OH)D) deficiency has become an emerging public health problem due to its influence on skeletal and extraskeletal diseases. Bone health in patients with sickle cell disease (SCD) is especially compromised and they are more likely to have 25(OH)D deficiency than the general population. Despite this, there is little information on the efficacy of vitamin D3 (vitD3) prophylaxis and its role in improving bone mineral density (BMD) in this population. A prospective, longitudinal, single-center study was conducted with 136 children with SCD monitored at a tertiary referral hospital for SCD. Demographic, clinical and management data, 25(OH)D levels and bone densitometries (DXA) were collected. Eighty patients were included. There are significant differences between the means of each of 25(OH)D levels as a function of whether the patient started prophylactic treatment as an infant or not (35.71 vs. 27.89 ng/ml, respectively [p = .014]). In multivariate analysis, 800 IU daily dose was shown as a protective factor (p = .044) to reach optimal blood levels (≥30 ng/ml). According to Kaplan-Meier curves, patients younger than 10 years reached optimal levels earlier than older (p = .002), as well as those who were not being treated with hydroxyurea (p = .039). VitD3 prophylaxis is a safe practice in SCD. It is important to start this prophylactic treatment when the child is an infant. The daily regimen with 800 IU could be more effective for reaching levels ≥30 ng/ml, and, especially in preadolescent and adolescent patients, we should raise awareness about the importance of good bone health. •In Sickle Cell Disease there is a greater probability of vitamin D deficiency than general population.•Prophylaxis with vitamin D3 is a safe practice in patients with sickle cell disease.•It is especially important to start this prophylaxis in breastfeeding period and keep it beyond the first year of life.•Daily schedule with 800 IU could be more effective for reaching vitamin D levels ≥ 30 ng/ml.•In pre-adolescent and adolescent patients is especially where we should raise awareness of the care of a damaged bone health.
ISSN:8756-3282
1873-2763
DOI:10.1016/j.bone.2020.115228